Recipient: Carolo-Wilhelmina University of Technology in Braunschweig
Funding: GO-Bio initial conceptual phase 4 (01/12/2023 to 30/11/2024, EUR 119,988.00)

Project description:

Skin allografts have established themselves as the clinical standard for severe burn injuries due to the immediate restoration of the skin barrier. However, this treatment method is often accompanied by life-threatening side effects that occur as a result of an immune reaction including transplant rejection. The use of drugs for systemic immunosuppression for immunocompromised patients (e.g., severely burned patients) is excluded due to life-threatening risks. InCapSolution aims to improve the therapeutic efficacy of allogeneic skin grafts using a locally acting biopharmaceutical. The technology is based on a novel immunosuppressant in combination with transport nanoparticles and a special dosage form. After application of this biopharmaceutical to the allogeneic skin graft the rejection reaction is suppressed, which significantly increases the therapeutic efficacy of the treatment. An expansion of the field of application to other complex wounds and skin diseases is being planned.